Contrasting Titan Medical (NASDAQ:TMDIF) & Allurion Technologies (NYSE:ALUR)

Titan Medical (NASDAQ:TMDIF) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Risk & Volatility

Titan Medical has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.3, meaning that its share price is 130% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Titan Medical and Allurion Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0	0	0	0	N/A
Allurion Technologies	0	0	2	0	3.00

Allurion Technologies has a consensus target price of $5.00, indicating a potential upside of 476.70%. Given Allurion Technologies’ higher probable upside, analysts clearly believe Allurion Technologies is more favorable than Titan Medical.

Profitability

This table compares Titan Medical and Allurion Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	142.97%	88.73%
Allurion Technologies	-117.30%	N/A	-85.06%

Institutional & Insider Ownership

0.0% of Titan Medical shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by company insiders. Comparatively, 20.0% of Allurion Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Titan Medical and Allurion Technologies’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63 million	0.23	$6.95 million	$0.05	0.72
Allurion Technologies	$53.47 million	0.78	-$80.61 million	($3.79)	-0.23

Titan Medical has higher earnings, but lower revenue than Allurion Technologies. Allurion Technologies is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Titan Medical beats Allurion Technologies on 7 of the 13 factors compared between the two stocks.

About Titan Medical

Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada.

About Allurion Technologies

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.